Patent Yard Sign in
Canadian application, no grantCanada

Pyridomorphinans, thienomorphinans and use thereof

CA 2380814 A1 · Owner: Southern Research Institute · Inventors: Ananthan, Subramaniam

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Compounds represented by formulae (I) and (II) wherein each of Y X and R , individually is selected from the group consisting of hydrogen hydroxy, halo, CF3, NO2, CN, NH2, COR1 and CO2R2 wherein R1 is selected from the group consisting of alkyl, aryl, alkaryl, and NH2 and R2 is selected from the group , consisting of alkyl aryl and aralkyl, and provided that at least one of Y X, and R is other than H; and pharmaceutically acceptable salts thereof are provided. Compounds of the formula are useful as analgesics for treating pain as immunomodulators and for treating drug abuse.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed August 14, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 14, 2020.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 14, 2022.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledAugust 14, 2000
GrantedNo grant recorded
Term endedAugust 14, 2020
Patent numberCA 2380814 A1
Classification (IPC)C07D495/18 +2 more

Timeline

Timeline From CIPO dates

2001200320052007200920112013201520172019Application filedAug 14, 2000Term endedAug 14, 2020

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.